BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients
Status:
Completed
Trial end date:
2019-06-11
Target enrollment:
Participant gender:
Summary
This is a Phase 2 multicenter, open-label, non-randomized study to examine the safety and
effectiveness of BPM31510 administered over 144-hours (two 72-hour 110mg/Kg doses) continuous
intravenous (IV) infusion in combination with gemcitabine in advanced pancreatic cancer
patients as 2nd / 3rd line therapy. The study will enroll up to 25 patients in the US and
Europe.